ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 608

Effect Of Renal Damage On Extra-Renal Organ Damage and Mortality In Patients With Systemic Lupus Erythematosus (SLE): A Longitudinal Cohort Study Of 756 Patients

Chi Chiu Mok1, Ling Yin Ho1, Kar Li Chan1 and Chi Hung To2, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Tuen Mun Hospital, Hong Kong, Hong Kong

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus and renal disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: To study the effect of renal damage on extra-renal organ damage and mortality in patients with SLE.

Methods: Patients who fulfilled >=4 ACR criteria for SLE between 1995 and 2011 were longitudinally followed.  Organ damage in 12 systems was assessed by the ACR SLICC damage scores (SDI).  The cumulative rate of survival was studied by Kaplan-Meier’s plot.  For those who died during the disease course, data were censored at the time of death.  For those who were lost follow-up, data were censored at the time of last clinic visits.  Comparison of extra-renal organ damage and survival rate was made between patients with and without renal damage during the course of SLE. 

Results:

756 SLE patients were studied (696 women, 92%).  All were ethnic Chinese.  The mean age of onset of SLE was 32.7±13.6 years and the mean follow-up time of the entire cohort of patients was 9.4±7.4 years.  76 (10%) patients died during the course of illness and 34 (4.5%) patients were lost to follow-up.  26 (3.4%) patients developed end stage renal failure (ESRF).  The main contributing causes of death in those 76 patients were: infection (49%), cardiovascular events (12%), cerebrovascular events (13%), cancer (11%), suicide (3%) and others (13%).  Overall, renal damage occurred in 84 (11%) patients (64% with impaired glomerular filtration rate; 6% persistently heavy proteinuria; 30% ESRF).  Compared with patients without renal damage (renal SDI=0), those with renal damage had significantly higher incidence of damage in the eyes, central nervous system, pulmonary system, cardiovascular system, musculoskeletal system, gonads and the endocrine system (P<0.001 in all).  The corresponding mean SDI scores in these systems were also significantly higher in patients with renal damage than those without.  The cumulative survival rates of our patients were 94% at 5 years, 90% at 10 years and 86% at 15 years.  Patients with renal damage had significantly higher mortality than those without (log rank test; p<0.001).  The age and sex adjusted hazard ratio for mortality in patients with renal damage relative to those without renal damage was 3.55 (95% CI 2.22-5.66; <0.001).

Conclusion:

In patients with SLE, renal damage significantly and adversely affects survival.  The presence of renal damage significantly increases the incidence of extra-renal organ damage, particularly in the cardiovascular, pulmonary, neuropsychiatric, ophthalmological, musculoskeletal, gonadal and endocrine systems.


Disclosure:

C. C. Mok,

Pfizer Inc,

8,

GlaxoSmithKline,

8,

Mundipharma Pte Ltd,

9;

L. Y. Ho,
None;

K. L. Chan,
None;

C. H. To,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-renal-damage-on-extra-renal-organ-damage-and-mortality-in-patients-with-systemic-lupus-erythematosus-sle-a-longitudinal-cohort-study-of-756-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology